---
title: "Global Blood Grouping and Phenotyping Reagents Market Research Report 2025(Status and Outlook)"
datePublished: Fri Sep 26 2025 20:00:42 GMT+0000 (Coordinated Universal Time)
cuid: cmg19o9n7000202ky6qcd4p0y
slug: global-blood-grouping-and-phenotyping-reagents-market-research-report-2025status-and-outlook-1

---

# Global Blood Grouping and Phenotyping Reagents Market Research Report 2025(Status and Outlook)

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>Global blood grouping and phenotyping reagents market was valued at <strong>USD 1.2 billion in 2024</strong> and is projected to reach <strong>USD 2.1 billion by 2032</strong>,  growing at a <strong>CAGR of 7.3% f</strong>orecast period.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/291703/blood-grouping-phenotyping-reagents-market">
            https://www.24chemicalresearch.com/download-sample/291703/blood-grouping-phenotyping-reagents-market</a></b></div><br><p>
</p><p>Blood grouping reagents are essential tools used in blood banks and hospitals to determine blood types (ABO and Rh) for safe blood transfusions. Phenotyping reagents go further by identifying specific red blood cell antigens beyond the basic blood groups, which is crucial for patients requiring multiple transfusions or with rare blood types. These reagents include monoclonal antibodies, polyclonal antibodies, and antisera used in various testing methods.</p><p>
</p><p>The market growth is primarily driven by increasing surgical procedures requiring blood transfusions, rising prevalence of blood disorders, and growing awareness about blood safety. Technological advancements in reagent development, such as monoclonal antibody-based reagents, are improving test accuracy and efficiency. However, stringent regulatory requirements for reagent approval and the high cost of advanced reagents may restrain market growth. The COVID-19 pandemic significantly increased demand for blood grouping reagents as blood banks worked to maintain adequate supplies during the crisis.</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Rising Prevalence of Blood Transfusion Procedures to Fuel Market Growth</strong></p><p>
</p><p>Global blood grouping and phenotyping reagents market is experiencing significant growth due to the increasing number of blood transfusion procedures worldwide. With over 118 million blood donations collected globally each year, the demand for accurate blood typing and cross-matching reagents has never been higher. Blood grouping reagents play a critical role in ensuring transfusion safety by preventing mismatched transfusions that can lead to fatal hemolytic reactions. The growing surgical procedures, trauma cases, and chronic diseases requiring blood transfusions are driving consistent demand for these essential diagnostic reagents.</p><p>
</p><p style="text-align:center"><strong>Technological Advancements in Blood Typing Methods to Accelerate Adoption</strong></p><p>
</p><p>Recent technological advancements in blood typing methodologies are revolutionizing the market. Automated blood grouping systems that offer higher throughput, reduced human error, and faster turnaround times are gaining rapid adoption in blood banks and hospitals. These systems require specialized reagents that are compatible with automated platforms, creating new revenue streams for manufacturers. Molecular blood grouping techniques, which provide more precise antigen detection than traditional serological methods, are particularly gaining traction in developed markets. The transition from manual to automated and molecular methods is expected to sustain market growth through the forecast period.</p><p>
</p><p style="text-align:center"><strong>Stringent Regulatory Standards for Blood Safety to Drive Reagent Demand</strong></p><p>
</p><p>Increasingly stringent regulatory requirements for blood safety and transfusion medicine are compelling healthcare facilities to invest in high-quality blood grouping reagents. Regulatory bodies worldwide are mandating more comprehensive blood typing protocols, including extended phenotyping in certain patient populations. This regulatory push is particularly evident in developed markets where healthcare systems are implementing more rigorous standards to prevent transfusion-related adverse events. The growing emphasis on blood safety is expected to maintain steady demand for advanced blood grouping and phenotyping reagents across all healthcare settings.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>High Cost of Automated Blood Typing Systems to Limit Market Penetration</strong></p><p>
</p><p>While automated blood grouping systems offer numerous advantages, their high capital and operational costs present a significant barrier to widespread adoption, particularly in price-sensitive markets. A complete automated blood typing workstation can cost upwards of $100,000, with additional expenses for maintenance and proprietary reagents. This substantial investment requirement prevents many smaller healthcare facilities and blood banks in developing regions from upgrading their blood typing infrastructure. The cost sensitivity in these markets continues to favor traditional manual methods, thereby restraining the growth potential for advanced blood grouping reagents.</p><p>
</p><p style="text-align:center"><strong>Shortage of Skilled Technicians for Advanced Blood Typing Techniques</strong></p><p>
</p><p>The implementation of sophisticated blood grouping technologies is being hampered by a global shortage of trained laboratory personnel. Molecular blood typing methods and automated systems require specialized technical expertise that is not always available, especially in resource-limited settings. This skills gap creates operational challenges for healthcare facilities attempting to transition to more advanced blood typing platforms. The training requirements and associated costs for maintaining qualified staff add another layer of complexity that slows the adoption of newer blood grouping reagents and technologies.</p><p>
</p><p style="text-align:center"><strong>Regulatory Hurdles in Reagent Approval Processes</strong></p><p>
</p><p>The blood grouping reagents market faces significant regulatory challenges that can delay product launches and increase development costs. The approval process for new blood typing reagents is particularly stringent due to the critical nature of transfusion medicine. Manufacturers must navigate complex regulatory pathways that vary by region, often requiring extensive clinical validation studies. These regulatory hurdles are especially challenging for smaller companies and can discourage innovation in the market. The time and resources required to obtain necessary approvals continue to be a restraint for market growth.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Emerging Markets Present Significant Growth Potential</strong></p><p>
</p><p>Developing economies represent a substantial growth opportunity for blood grouping reagent manufacturers. As healthcare infrastructure improves in these regions, there is increasing investment in blood bank modernization and transfusion safety. Many emerging markets are transitioning from basic blood typing to more comprehensive testing protocols, creating demand for a wider range of blood grouping reagents. The growing middle-class population and increasing access to healthcare services in these regions are expected to drive market expansion through the forecast period.</p><p>
</p><p style="text-align:center"><strong>Development of Novel Reagents for Rare Blood Types</strong></p><p>
</p><p>The identification and characterization of rare blood group antigens present a significant opportunity for market players. There is growing clinical need for reagents that can detect rare blood group phenotypes, particularly for patients who require frequent transfusions or have developed antibodies. The development of specialized reagents for these niche applications commands premium pricing and creates differentiation opportunities for manufacturers. Research into new blood group systems and the corresponding antibodies continues to reveal potential areas for product development in this segment.</p><p>
</p><p style="text-align:center"><strong>Integration of Molecular Typing with Traditional Serology</strong></p><p>
</p><p>The convergence of molecular biology techniques with conventional serological methods is creating new opportunities in the blood grouping reagents market. Hybrid systems that combine the strengths of both approaches are gaining attention in transfusion medicine. These integrated solutions allow for more comprehensive blood group profiling while maintaining the practical advantages of traditional methods. Manufacturers that can develop reagents and systems supporting this combined approach are well-positioned to capitalize on this emerging trend in blood typing technology.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Maintaining Reagent Quality and Consistency</strong></p><p>
</p><p>Blood grouping reagents present unique quality control challenges due to their biological nature and critical role in transfusion safety. Manufacturers must maintain rigorous quality standards to ensure reagent consistency across production lots. The biological variability inherent in antibody-based reagents can lead to batch-to-batch variations that affect performance. These quality control challenges are compounded by the need to maintain adequate supplies of rare antibodies used in some phenotyping reagents. Ensuring consistent quality while scaling up production remains an ongoing challenge for market players.</p><p>
</p><p style="text-align:center"><strong>Competition from Alternative Technologies</strong></p><p>
</p><p>The blood grouping reagents market faces increasing competition from emerging technologies that could potentially disrupt traditional serological methods. Point-of-care blood typing devices and DNA-based typing methods are being developed that may reduce reliance on conventional reagents. While these technologies are not yet widely adopted, their potential to streamline blood typing workflows poses a long-term challenge to reagent manufacturers. Companies must continuously innovate to maintain their market position against these technological alternatives.</p><p>
</p><p style="text-align:center"><strong>Supply Chain Vulnerabilities for Critical Raw Materials</strong></p><p>
</p><p>The production of blood grouping reagents depends on the availability of specific biological raw materials, including human and animal sera containing desired antibodies. Disruptions in the supply of these critical components can significantly impact manufacturing operations. The COVID-19 pandemic highlighted vulnerabilities in global supply chains, with many reagent manufacturers experiencing shortages of key materials. Developing resilient supply chains and alternative sourcing strategies remains an ongoing challenge for maintaining consistent reagent production and availability.</p><p>
<strong>MARKET TRENDS</strong></p><p>
<strong>Automation in Blood Typing to Drive Market Growth</strong></p><p>
</p><p>Global blood grouping and phenotyping reagents market is witnessing significant growth due to the increasing adoption of automated systems in blood banks and diagnostic laboratories. Automated platforms reduce human error, improve turnaround times, and enhance the accuracy of blood typing results. Recent data indicates that over <strong>65% of large-scale blood banks</strong> in developed nations have transitioned to automated blood grouping systems. This shift is particularly crucial in transfusion medicine, where precision is paramount to prevent adverse reactions. Furthermore, the integration of artificial intelligence in blood grouping analyzers is enabling real-time data interpretation and quality control, creating new opportunities for market expansion.</p><p>
<strong>Other Trends</strong></p><p>
</p><p style="text-align:center"><strong>Rising Demand for Rare Blood Typing</strong></p><p>
</p><p>The growing need for rare blood type identification is fueling demand for advanced phenotyping reagents. With increasing global mobility and multicultural populations, healthcare providers are encountering more complex transfusion requirements. Current estimates suggest that <strong>1 in 1,000 individuals</strong> requires specialized blood matching beyond standard ABO/Rh typing. This has led to increased adoption of extended phenotyping panels that can identify over 30 different blood group antigens. The market for these specialized reagents is projected to grow at nearly <strong>8% annually</strong> as hospitals and blood banks expand their testing capabilities to meet diverse patient needs.</p><p>
<strong>Molecular Blood Grouping Gains Traction</strong></p><p>
</p><p>Molecular techniques are increasingly complementing traditional serological methods in blood grouping. DNA-based testing provides definitive results in cases where serology may be inconclusive, such as patients with recent transfusions or autoimmune conditions. While currently accounting for approximately <strong>15% of total blood typing procedures</strong>, molecular methods are growing at nearly twice the rate of conventional techniques. This trend is particularly evident in prenatal testing and donor screening programs, where genetic analysis can predict fetal blood group status or identify donors with rare phenotypes more efficiently. The development of multiplex PCR-based systems has significantly reduced the cost and complexity of molecular blood grouping, making it more accessible to routine laboratories.</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Strategic Collaborations and Product Innovations Drive Market Competition</strong></p><p>
</p><p>Global blood grouping and phenotyping reagents market features a moderately competitive landscape with established diagnostic companies and specialized biotechnology firms vying for market share. <strong>Bio-Rad Laboratories, Inc.</strong> emerges as a dominant player, holding approximately 22% of the market share in 2023, owing to its comprehensive serological testing solutions and strong distribution network across 120 countries.</p><p>
</p><p><strong>Grifols, S.A.</strong> and <strong>Ortho Clinical Diagnostics</strong> (a subsidiary of QuidelOrtho) collectively account for nearly 30% of the market revenue, primarily due to their extensive blood banking solutions and automated testing platforms. These companies have significantly invested in R&amp;D, with Grifols allocating over 8% of its annual revenue to develop next-generation blood typing reagents.</p><p>
</p><p>Meanwhile, <strong>Thermo Fisher Scientific</strong> has been expanding its footprint through strategic acquisitions, including the recent purchase of The Binding Site Group to enhance its specialty diagnostics portfolio. This move positions Thermo Fisher as a formidable competitor in the immunohematology space.</p><p>
</p><p>Regional players like <strong>Medion Diagnostics AG</strong> and <strong>Alba Bioscience</strong> maintain strong positions in their respective markets through specialized product offerings and cost-effective solutions tailored for emerging economies. These companies are increasingly forming distribution partnerships with global players to expand their geographical presence.</p><p>
<strong>List of Key Blood Grouping and Phenotyping Reagent Companies</strong></p><p>
</p><p><strong>Bio-Rad Laboratories, Inc. (U.S.)</strong></p><p>Grifols, S.A. (Spain)</p><p>Ortho Clinical Diagnostics (U.S.)</p><p>Thermo Fisher Scientific Inc. (U.S.)</p><p><strong>Medion Diagnostics AG (Switzerland)</strong></p><p>Alba Bioscience (UK)</p><p>Biotest AG (Germany)</p><p>Immucor, Inc. (U.S.)</p><p>Quotient Limited (Switzerland)â</p><p>
<strong>Segment Analysis:</strong></p><p>
<strong>By Type</strong></p><p>
</p><p><strong>Monoclonal Antibody Reagents Lead the Market Due to High Specificity and Consistency</strong></p><p>
</p><p>The Global Blood Grouping and Phenotyping Reagents market is segmented based on type into:</p><p>
</p><p>Monoclonal antibodies</p><p>
</p><p>Polyclonal antibodies</p><p>Antisera</p><p>Molecular typing reagents</p><p>
</p><p>Others</p><p>
<strong>By Application</strong></p><p>
</p><p><strong>Blood Banks Segment Dominates Due to High Volume of Routine Blood Typing</strong></p><p>
</p><p>The market is segmented based on application into:</p><p>
</p><p>Blood banks</p><p>Hospitals</p><p>Clinical laboratories</p><p>Research institutions</p><p>Others</p><p>
<strong>By Technology</strong></p><p>
</p><p><strong>Microplate Technology Segment Holds Significant Share Due to High Throughput Capabilities</strong></p><p>
</p><p>The market is segmented based on technology into:</p><p>
</p><p>Microplate</p><p>Gel cards</p><p>Rapid tests</p><p>Automated systems</p><p>Others</p><p>
<strong>By Test Type</strong></p><p>
</p><p><strong>ABO/Rh Typing Maintains Dominance as Standard Pre-Transfusion Testing</strong></p><p>
</p><p>The market is segmented based on test type into:</p><p>
</p><p>ABO/Rh typing</p><p>Extended phenotyping</p><p>Antibody screening</p><p>Cross-matching</p><p>Others</p><p>
<strong>Regional Analysis: Global Blood Grouping and Phenotyping Reagents Market</strong></p><p>
</p><p><strong>North America</strong></p><p>
</p><p>North America remains a dominant player in the blood grouping and phenotyping reagents market, driven by advanced healthcare infrastructure and significant investment in blood transfusion safety. The U.S. leads due to stringent regulatory oversight by the FDA and CDC, ensuring high adoption of standardized testing protocols. Key players like Bio-Rad Medical Diagnostics and the American National Red Cross reinforce market growth with innovative product launches and extensive blood bank networks. The region's emphasis on precision medicine and rising demand for transfusion-compatible blood products in hospitals and trauma centers continue to propel market expansion. However, the high cost of advanced reagents and increasing preference for automation in blood testing may shape future procurement strategies.</p><p>
</p><p><strong>Europe</strong></p><p>
</p><p>Europe's market is characterized by rigorous adherence to EU directives on blood safety and robust R&amp;D initiatives in immunohematology. Germany and the UK are frontrunners, leveraging collaborations between public health agencies and manufacturers like Grifols and Biotest to enhance reagent accuracy. The growing prevalence of chronic diseases requiring blood transfusions, coupled with an aging population, strengthens demand. However, pricing pressures from generic alternatives and centralized procurement policies in some countries could moderate growth. The region’s focus on molecular phenotyping techniques and rare blood type identification presents new opportunities, particularly in precision transfusion medicine.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
</p><p>This region exhibits the fastest growth, fueled by improving healthcare access and large-scale blood donation drives in India and China. Government initiatives, such as India’s National Blood Policy, aim to standardize testing, boosting demand for quality reagents. Local manufacturers like Siwa Biotech compete with global firms by offering cost-effective solutions tailored to high-volume testing needs. While hospital-based blood banks dominate consumption, emerging private diagnostic chains and research institutes are creating new avenues. Challenges include uneven regulatory enforcement and infrastructure gaps in rural areas, though urbanization and rising awareness of transfusion safety are driving long-term potential.</p><p>
</p><p><strong>South America</strong></p><p>
</p><p>Market growth here is steady but constrained by economic volatility and fragmented healthcare systems. Brazil leads reagent adoption, supported by an extensive public blood bank network and increasing surgical procedures. However, reliance on imported products due to limited local manufacturing escalates costs, particularly in smaller economies. Efforts to modernize blood transfusion services through partnerships with global players could unlock opportunities. Political instability and inconsistent funding for public health programs remain hurdles, though initiatives like Argentina’s national blood system reform aim to address these gaps.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
</p><p>The MEA market is nascent but evolving, led by the Gulf Cooperation Council (GCC) countries investing in advanced blood banking infrastructure. Saudi Arabia and the UAE prioritize reagent quality through collaborations with European and U.S. suppliers, while South Africa’s well-established private healthcare sector drives regional demand. Challenges persist in low-income nations due to inadequate cold chain logistics and testing facilities. However, rising medical tourism and expanding hospital networks signal gradual improvement, with international aid programs playing a pivotal role in enhancing transfusion safety across sub-Saharan Africa.</p><p>
<strong>Report Scope</strong></p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for Blood Grouping and Phenotyping Reagents, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Blood Grouping and Phenotyping Reagents companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global Blood Grouping and Phenotyping Reagents Market?</strong></p><p>
</p><p>-&gt; Global blood grouping and phenotyping reagents market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.1 billion by 2032, growing at a CAGR of 7.3%.</p><p>
<strong>Which key companies operate in Global Blood Grouping and Phenotyping Reagents Market?</strong></p><p>
</p><p>-&gt; Key players include Bio-Rad Medical Diagnostics, Grifols S.A., Thermo Fisher Scientific, Ortho Clinical Diagnostics, and Quotient Limited, among others.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Key growth drivers include rising demand for blood transfusions, increasing prevalence of chronic diseases, and technological advancements in blood testing.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p>-&gt; North America holds the largest market share, while Asia-Pacific is expected to witness the fastest growth during the forecast period.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include automation in blood testing, development of novel reagents, and increasing adoption of molecular typing techniques.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/291703/blood-grouping-phenotyping-reagents-market">
            https://www.24chemicalresearch.com/reports/291703/blood-grouping-phenotyping-reagents-market</a></b></div><br>
            <b>Table of Content:</b><p>Table of Contents<br />
1 Research Methodology and Statistical Scope<br />
1.1 Market Definition and Statistical Scope of Blood Grouping and Phenotyping Reagents<br />
1.2 Key Market Segments<br />
1.2.1 Blood Grouping and Phenotyping Reagents Segment by Type<br />
1.2.2 Blood Grouping and Phenotyping Reagents Segment by Application<br />
1.3 Methodology & Sources of Information<br />
1.3.1 Research Methodology<br />
1.3.2 Research Process<br />
1.3.3 Market Breakdown and Data Triangulation<br />
1.3.4 Base Year<br />
1.3.5 Report Assumptions & Caveats<br />
2 Blood Grouping and Phenotyping Reagents Market Overview<br />
2.1 Global Market Overview<br />
2.1.1 Global Blood Grouping and Phenotyping Reagents Market Size (M USD) Estimates and Forecasts (2019-2030)<br />
2.1.2 Global Blood Grouping and Phenotyping Reagents Sales Estimates and Forecasts (2019-2030)<br />
2.2 Market Segment Executive Summary<br />
2.3 Global Market Size by Region<br />
3 Blood Grouping and Phenotyping Reagents Market Competitive Landscape<br />
3.1 Global Blood Grouping and Phenotyping Reagents Sales by Manufacturers (2019-2024)<br />
3.2 Global Blood Grouping and Phenotyping Reagents Revenue Market Share by Manufacturers (2019-2024)<br />
3.3 Blood Grouping and Phenotyping Reagents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)<br />
3.4 Global Blood Grouping and Phenotyping Reagents Average Price by Manufacturers (2019-2024)<br />
3.5 Manufacturers Blood Grouping and Phenotyping Reagents Sales Sites, Area Served, Product Type<br />
3.6 Blood Grouping and Phenotyping Reagents Market Competitive Situation and Trends<br />
3.6.1 Blood G</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/291703/blood-grouping-phenotyping-reagents-market">
            https://www.24chemicalresearch.com/reports/291703/blood-grouping-phenotyping-reagents-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>